Chondrosarcoma Market

DelveInsight's "Chondrosarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chondrosarcoma market report provides current treatment practices, emerging drugs, Chondrosarcoma market share of the individual therapies, current and forecasted Chondrosarcoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chondrosarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chondrosarcoma market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Chondrosarcoma Disease Understanding and Treatment Algorithm

The DelveInsight’s Chondrosarcoma market report gives a thorough understanding of the Chondrosarcoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

 

Chondrosarcoma is a rare type of bone cancer that consists predominantly of cartilage. It mostly affects the pelvis, upper arms (humerus), thighs (femur), ribs, and shoulder blades (scapula) and is the most common in people older than 40 years.

Rising funding for R&D and clinical trials, as well as FDA approvals, are major driving forces for the chondrosarcoma market. Major players are funding a large amounts of money in new product development for effective cures which is another key driver for the market.

 

Types

There are several types of chondrosarcoma that are named based on the way that they appear under the microscope. These include:

 

  • Conventional chondrosarcoma
  • Clear cell chondrosarcoma
  • Myxoid chondrosarcoma
  • Mesenchymal chondrosarcoma
  • Dedifferentiated chondrosarcoma

 

Chondrosarcoma Symptoms

People with chondrosarcoma usually do not feel sick. They may be able to feel a boney bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor.

 

Chondrosarcoma Diagnosis

A bone tumor is often first discovered on x-ray after a physical exam. It can be difficult to tell the difference between a benign bone tumor & chondrosarcoma on x-ray. Additional tests, including a bone scan, CT scan, MRI and PET scan, can provide more information about the tumor. Ultimately, biopsy of the tumor is the only way to make a definite diagnosis of chondrosarcoma. After the biopsy procedure, a pathologist looks at the tumor’s cells under the microscope to make a diagnosis.

 

Chondrosarcoma Treatment

Complete surgical removal of the tumor, along with a wide margin of healthy tissue, has historically been the preferred treatment of chondrosarcoma. Limb salvage surgery is a common treatment technique, and amputation is only used occasionally for advanced or recurrent disease. Most chondrosarcomas (with the exception of mesenchymal chondrosarcoma) do not respond to chemotherapy or radiation therapy. This makes surgical management crucial in the treatment of chondrosarcoma. In rare situations where the skull is involved, proton radiation therapy may be helpful.

It covers the details of conventional and current medical therapies available in the Chondrosarcoma market for the treatment of the condition. It also provides Chondrosarcoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Chondrosarcoma Epidemiology

The Chondrosarcoma epidemiology section provides insights about the historical and current Chondrosarcoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chondrosarcoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chondrosarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

  • According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer.
  • According to the American Cancer Society, Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20.
  • According to the researchers, Chondrosarcoma is slightly more common in males than in females
  • As per Faten Limaiem et al. (2019), Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance. The most common locations of involvement of Chondrosarcoma include the bones of the axial skeleton (pelvis, scapula, sternum, and ribs) followed by the proximal femur and proximal humerus.

 

Country Wise- Chondrosarcoma Epidemiology

The epidemiology segment also provides the Chondrosarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chondrosarcoma Drug Chapters

The drug chapter segment of the Chondrosarcoma report encloses the detailed analysis of Chondrosarcoma marketed drugs and late-stage (Phase-III and Phase-II) Chondrosarcoma pipeline drugs. It also helps to understand the Chondrosarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Chondrosarcoma Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Chondrosarcoma treatment.

 

Chondrosarcoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Chondrosarcoma treatment.

 

  • AG-120: Agios Pharmaceuticals, Inc.
  • INBRX-109: Inhibrx, Inc
  • Ifosfamide: Atlanthera
  • And Others

 

Chondrosarcoma Market Outlook

The Chondrosarcoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chondrosarcoma market trends by analyzing the impact of current Chondrosarcoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Chondrosarcoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chondrosarcoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Chondrosarcoma market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Chondrosarcoma market in 7MM.

The United States: Chondrosarcoma Market Outlook

This section provides the total Chondrosarcoma market size and market size by therapies in the United States.

 

EU-5 Countries: Chondrosarcoma Market Outlook

The total Chondrosarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan: Chondrosarcoma Market Outlook

The total Chondrosarcoma market size and market size by therapies in Japan is also mentioned.

Chondrosarcoma Drugs Uptake

This section focuses on the rate of uptake of the potential Chondrosarcoma drugs recently launched in the Chondrosarcoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chondrosarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Chondrosarcoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Chondrosarcoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Chondrosarcoma Pipeline Development Activities

The Chondrosarcoma report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chondrosarcoma key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Chondrosarcoma report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Chondrosarcoma emerging therapies.

Reimbursement Scenario in Chondrosarcoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Chondrosarcoma market trends, we take KOLs and SMEs ' opinion working in the Chondrosarcoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chondrosarcoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chondrosarcoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Chondrosarcoma Market Report

  • The report covers the descriptive overview of Chondrosarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Chondrosarcoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chondrosarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Chondrosarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chondrosarcoma market

 

Report Attribute/Metric Details
Study Period 2019- 2032
Geographies Covered 7MM
Market Size USD XX Miliion
CAGR XX%
Key Companies
  • Agios Pharmaceuticals
  • PharmaMar
  • Forma Therapeutics
  • Inhibrx
  • Eli Lilly and Company
  • Akorn, Inc.
  • Epizyme, Inc.
  • Mylan N.V.
  • AbbVie Inc.
  • Abbott
  • Baxter
  • Bayer AG
  • Agios, Inc.
  • Novartis AG

Chondrosarcoma Market Report Highlights

  • In the coming years, the Chondrosarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Chondrosarcoma. The launch of emerging therapies will significantly impact the Chondrosarcoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chondrosarcoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chondrosarcoma Report Insights

  • Chondrosarcoma Patient Population
  • Therapeutic Approaches
  • Chondrosarcoma Pipeline Analysis
  • Chondrosarcoma Market Size
  • Chondrosarcoma Market Trends
  • Chondrosarcoma Market Opportunities
  • Impact of upcoming Chondrosarcoma Therapies

Chondrosarcoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Chondrosarcoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Chondrosarcoma Market
  • Chondrosarcoma Drugs Uptake

Chondrosarcoma Report Assessment

  • Current Treatment Practices
  • Chondrosarcoma Unmet Needs
  • Chondrosarcoma Pipeline Product Profiles
  • Chondrosarcoma Market Attractiveness
  • Chondrosarcoma Market Drivers
  • Chondrosarcoma Market Barriers

Key Questions

Chondrosarcoma Market Insights:

  • What was the Chondrosarcoma drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Chondrosarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chondrosarcoma market size during the forecast period (2019-2032)?
  • At what CAGR, the Chondrosarcoma market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Chondrosarcoma market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Chondrosarcoma market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Chondrosarcoma?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Chondrosarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chondrosarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chondrosarcoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chondrosarcoma during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Chondrosarcoma treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Chondrosarcoma in the USA, Europe, and Japan?
  • What are the Chondrosarcoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chondrosarcoma?
  • How many therapies are in-development by each company for Chondrosarcoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Chondrosarcoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chondrosarcoma and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Chondrosarcoma?
  • What are the global historical and forecasted market of Chondrosarcoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market
  • To understand the future market competition in the Chondrosarcoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chondrosarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chondrosarcoma market
  • To understand the future market competition in the Chondrosarcoma market

1. Key Insights

2. Executive Summary of Chondrosarcoma

3. Competitive Intelligence Analysis for Chondrosarcoma

4. Chondrosarcoma: Market Overview at a Glance

4.1. Chondrosarcoma Total Market Share (%) Distribution in 2019

4.2. Chondrosarcoma Total Market Share (%) Distribution in 2032

5. Chondrosarcoma: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Chondrosarcoma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Chondrosarcoma Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Chondrosarcoma Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Chondrosarcoma Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Chondrosarcoma Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Chondrosarcoma Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Chondrosarcoma Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Chondrosarcoma Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Chondrosarcoma Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Chondrosarcoma Treatment and Management

8.2. Chondrosarcoma Treatment Algorithm

9. Chondrosarcoma Unmet Needs

10. Key Endpoints of Chondrosarcoma Treatment

11. Chondrosarcoma Marketed Products

11.1. List of Chondrosarcoma Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Chondrosarcoma Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Chondrosarcoma: Seven Major Market Analysis

13.1. Key Findings

13.2. Chondrosarcoma Market Size in 7MM

13.3. Chondrosarcoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Chondrosarcoma Total Market Size in the United States

15.1.2. Chondrosarcoma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Chondrosarcoma Total Market Size in Germany

15.3.2. Chondrosarcoma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Chondrosarcoma Total Market Size in France

15.4.2. Chondrosarcoma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Chondrosarcoma Total Market Size in Italy

15.5.2. Chondrosarcoma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Chondrosarcoma Total Market Size in Spain

15.6.2. Chondrosarcoma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Chondrosarcoma Total Market Size in the United Kingdom

15.7.2. Chondrosarcoma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Chondrosarcoma Total Market Size in Japan

15.8.3. Chondrosarcoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Chondrosarcoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Chondrosarcoma Epidemiology (2019-2032)

Table 2: 7MM Chondrosarcoma Diagnosed and Treatable Cases (2019-2032)

Table 3: Chondrosarcoma Epidemiology in the United States (2019-2032)

Table 4: Chondrosarcoma Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Chondrosarcoma Epidemiology in Germany (2019-2032)

Table 6: Chondrosarcoma Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Chondrosarcoma Epidemiology in France (2019-2032)

Table 8: Chondrosarcoma Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Chondrosarcoma Epidemiology in Italy (2019-2032)

Table 10: Chondrosarcoma Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Chondrosarcoma Epidemiology in Spain (2019-2032)

Table 12: Chondrosarcoma Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Chondrosarcoma Epidemiology in the UK (2019-2032)

Table 14: Chondrosarcoma Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Chondrosarcoma Epidemiology in Japan (2019-2032)

Table 16: Chondrosarcoma Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Chondrosarcoma Epidemiology (2019-2032)

Figure 2: 7MM Chondrosarcoma Diagnosed and Treatable Cases (2019-2032)

Figure 3: Chondrosarcoma Epidemiology in the United States (2019-2032)

Figure 4: Chondrosarcoma Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Chondrosarcoma Epidemiology in Germany (2019-2032)

Figure 6: Chondrosarcoma Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Chondrosarcoma Epidemiology in France (2019-2032)

Figure 8: Chondrosarcoma Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Chondrosarcoma Epidemiology in Italy (2019-2032)

Figure 10: Chondrosarcoma Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Chondrosarcoma Epidemiology in Spain (2019-2032)

Figure 12: Chondrosarcoma Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Chondrosarcoma Epidemiology in the UK (2019-2032)

Figure 14: Chondrosarcoma Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Chondrosarcoma Epidemiology in Japan (2019-2032)

Figure 16: Chondrosarcoma Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

  • Agios Pharmaceuticals
  • PharmaMar
  • Forma Therapeutics
  • Inhibrx
  • Eli Lilly and Company
  • Akorn, Inc.
  • Epizyme, Inc.
  • Mylan N.V.
  • AbbVie Inc.
  • Abbott
  • Baxter
  • Bayer AG
  • Agios, Inc.
  • Novartis AG

Forward to Friend

Need A Quote